HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (3- pyridinyl)- 1- (4- pyridinyl)- 2- propen- 1- one

6-phosphofructo-2-kinase-fructose-2,6-bisphosphatase isozymes inhibitor; structure in first source

Also Known As:

3PO compound

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one: 8

Experts

1.	Lea, Michael A: 2 articles (04/2016 - 11/2015)
2.	Chesney, Jason: 2 articles (01/2014 - 08/2013)
3.	Imbert-Fernandez, Yoannis: 2 articles (01/2014 - 08/2013)
4.	Klarer, Alden C: 2 articles (01/2014 - 08/2013)
5.	O'Neal, Julie: 2 articles (01/2014 - 08/2013)
6.	Telang, Sucheta: 2 articles (01/2014 - 08/2013)
7.	Haraldsen, Guttorm: 1 article (01/2020)
8.	Hol, Johanna: 1 article (01/2020)
9.	Lundbäck, Peter: 1 article (01/2020)
10.	Skålhegg, Bjørn Steen: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/23/2014 - "One family member, PFKFB3, has been shown to be highly expressed and activated in human cancer cells, and derivatives of a PFKFB3 inhibitor, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), are currently being developed in clinical trials. " 08/01/2013 - "Previously, a weak competitive inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was found to reduce the glucose metabolism and proliferation of cancer cells. " 04/01/2016 - "Previous studies have indicated that proliferation of cancer cells can be inhibited by treatment with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB) namely 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO). " 01/01/2020 - "Inhibition of the key glycolytic activator 6-phosphofructokinase 2/fructose-2,6-bisphosphatase-3 (PFKFB3) by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) strongly attenuates pathological angiogenesis in cancer and inflammation. "
2.	Inflammation (Inflammations) 01/01/2017 - "In this study, we investigated the effect of TLR2-activation on mitochondrial function and bioenergetics in primary RA-synovial fibroblast cells (RASFC), and further determined the role of glycolytic blockade on TLR2-induced inflammation in RASFC using glycolytic inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO). " 01/01/2020 - "Inhibition of the key glycolytic activator 6-phosphofructokinase 2/fructose-2,6-bisphosphatase-3 (PFKFB3) by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) strongly attenuates pathological angiogenesis in cancer and inflammation. "
3.	Sepsis (Septicemia) 01/01/2022 - "3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), the specific inhibitor of PFKFB3, and Gsdmd gene knockout significantly inhibited the inflammatory response and cell death caused by sepsis, thus alleviating intestinal damage and barrier dysfunction. "
4.	Pathologic Neovascularization 01/01/2020 - "Inhibition of the key glycolytic activator 6-phosphofructokinase 2/fructose-2,6-bisphosphatase-3 (PFKFB3) by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) strongly attenuates pathological angiogenesis in cancer and inflammation. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2013 - "We compared the effects of AA and combinations of AA with the glycolysis inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3-PO) on the viability of three non-small cell lung cancer (NSCLC) cell lines to the effects on an immortalized lung epithelial cell line. "

Related Drugs and Biologics

1.	Fructose
2.	Phosphotransferases (Kinase)
3.	Phenformin (Fenformin)
4.	Glucose (Dextrose)
5.	Phosphofructokinase-1 (Phosphofructokinase 1)